false 0001022899 Protagenic Therapeutics, Inc.new 0001022899 2024-09-17 2024-09-17 0001022899 PTIX:ProtagenicTherapeuticsInc.CommonStockMember 2024-09-17 2024-09-17 0001022899 PTIX:ProtagenicTherapeuticsInc.CommonStockWarrantsMember 2024-09-17 2024-09-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of Earliest Event Reported): September 17, 2024

 

PROTAGENIC THERAPEUTICS, INC.

 

(Exact name of Company as specified in its charter)

 

Delaware   001-12555   06-1390025

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

149 Fifth Avenue, Suite 500, New York, NY   10010
(Address of principal executive offices)   (Zip Code)

 

212-994-8200

 

(Company’s telephone number, including area code)

 

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
         
Protagenic Therapeutics, Inc. Common Stock   PTIX   Nasdaq
Protagenic Therapeutics, Inc. Common Stock Warrants   PTIXW   Nasdaq

 

 

 

 

 

 

Item 8.01 Other Events.

 

The Company has updated its currently anticipated clinical development milestones for PT00114:

 

  Q4 2024 Commence multiple dose portion of Phase I study for PT00114
     
  Q2 2025 Public availability of results from multiple dose portion of Phase I study for PT00114
     
  Q3 2025 Initiation of Phase IIa study for PT00114

 

The Company will provide further updates to its clinical development schedule as it becomes clearer.

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  PROTAGENIC THERAPEUTICS, INC.
     
Date: September 17, 2024 By: /s/ Alexander K. Arrow
  Name: Alexander K. Arrow
  Title: Chief Financial Officer

 

3

 

v3.24.3
Cover
Sep. 17, 2024
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 17, 2024
Entity File Number 001-12555
Entity Registrant Name Protagenic Therapeutics, Inc.new
Entity Central Index Key 0001022899
Entity Tax Identification Number 06-1390025
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 149 Fifth Avenue
Entity Address, Address Line Two Suite 500
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10010
City Area Code 212
Local Phone Number 994-8200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Protagenic Therapeutics, Inc. Common Stock  
Title of 12(b) Security Protagenic Therapeutics, Inc. Common Stock
Trading Symbol PTIX
Security Exchange Name NASDAQ
Protagenic Therapeutics, Inc. Common Stock Warrants  
Title of 12(b) Security Protagenic Therapeutics, Inc. Common Stock Warrants
Trading Symbol PTIXW
Security Exchange Name NASDAQ

Protagenic Therapeutics (NASDAQ:PTIXW)
Historical Stock Chart
From Sep 2024 to Oct 2024 Click Here for more Protagenic Therapeutics Charts.
Protagenic Therapeutics (NASDAQ:PTIXW)
Historical Stock Chart
From Oct 2023 to Oct 2024 Click Here for more Protagenic Therapeutics Charts.